Equity | Note 9 – Equity A. Stock option plans During each of the nine-month periods ended September 30, 2018 and September 30, 2017, 100,000 options were granted. The vesting period for the options is three years. The exercise prices for the options that were granted during the nine months ended September 30, 2018 and September 30, 2017, are $1.33 and $1.58, respectively. Those options expire up to five years after the date of grant. Any options which are forfeited or cancelled before expiration become available for future grants under the Company’s option plan. The fair value of each option granted to employees during the nine months ended September 30, 2018 and September 30, 2017 was estimated on the date of grant, using the Black-Scholes model and the following assumptions: Nine months ended September 30, 2018 2017 Expected dividend yield 0 % 0 % Expected volatility 80 % 74 % Risk-free interest rate 1.92 % 1.35 % Expected life - in years 2.33 3.5 1. Dividend yield of zero percent for all periods. 2. Expected average volatility represents a weighted average standard deviation rate for the price of the Company’s ordinary shares on Nasdaq. 3. Risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant. 4. For options granted during the nine months ended September 30, 2018 - estimated expected lives are based on historical grants data. For the nine months ended September 30, 2017 estimated expected lives are according to the simplified method. The Company’s options activity (including options to non-employees) during the nine months ended September 30, 2018 and options outstanding and options exercisable as of December 31, 2017 and September 30, 2018, are summarized in the following table: Number of Weighted options average exercise outstanding price per share Outstanding – December 31, 2017 1,495,000 $ 1.27 Options granted 100,000 1.33 Options expired or forfeited (196,335 ) 1.25 Options exercised (39,999 ) 0.86 Outstanding – September 30, 2018 1,358,666 1.29 Exercisable as of: December 31, 2017 681,321 $ 1.45 September 30, 2018 696,655 $ 1.39 The weighted average fair value of options granted during the nine months ended September 30, 2018 and during the nine months ended September 30, 2017 is $0.65 and $0.93, respectively, per option. The aggregate intrinsic value of outstanding options as of September 30, 2018 and December 31, 2017 is approximately $105 and $448, respectively. The aggregate intrinsic value of exercisable options as of September 30, 2018 and December 31, 2017 is approximately $85 and $206, respectively. The following table summarizes information about options outstanding and exercisable (including options to non-employees) as of September 30, 2018: Options outstanding Options exercisable Number Weighted Number Weighted Outstanding average Weighted Outstanding average Weighted as of remaining Average As of remaining Average Range of September 30, contractual Exercise September 30, contractual Exercise exercise price ($) 2018 life (years) Price 2018 life (years) Price 0.44- 0.90 420,000 2.23 $ 0.74 343,333 2.21 $ 0.74 1.07-1.68 713,666 3.65 1.23 128,322 2.99 1.23 2.32-2.36 185,000 0.59 2.35 185,000 0.59 2.35 3.03 40,000 0.98 $ 3.03 40,000 0.98 $ 3.03 1,358,666 2.72 696,655 1.85 As of September 30, 2018, there was approximately $247 of total unrecognized compensation cost related to non-vested stock-based compensation arrangements. That cost is expected to be recognized over a weighted-average period of approximately 1.2 years. During the nine months ended September 30, 2018 and September 30, 2017, the Company recorded stock-based compensation expenses in the amount of $180 and $238, respectively, in accordance with ASC 718, “Compensation-Stock Compensation.” B. Warrants 1. During the nine months ended September 30, 2018, no warrants expired or were exercised into ordinary shares. 2. As of September 30, 2018, there are remaining 40,000 outstanding warrants issued to one of the Company’s consultants during 2016 with a per share exercise price of $0.95. The warrants expire during 2019. C. Stock options and warrants in the amounts of 1,398,666 and 1,433,500 outstanding as of the nine months ended September 30, 2018 and 2017, respectively, have been excluded from the calculation of the diluted net loss from continuing operations per ordinary share because all such securities have an anti-dilutive effect for all periods presented. D. Shares to non-employees During the nine months ended September 30, 2018 and September 30, 2017, the Company issued 80,000 and 45,000 ordinary shares, respectively, to its consultants. The expenses that are recognized due to those grants are immaterial and are presented within ’stock-based compensation’ in the statement of changes in equity for the nine months ended September 30, 2018 and September 30, 2017. |